Peter Nielsen Net Worth

Peter Nielsen biography

Peter Henry Nielsen serves as Chairman of the Board, President, Chief Executive Officer, Co-Founder, Chief Financial Officer, Treasurer of the Company. Peter H. Nielsen. Mr. Nielsen co-founded Bio-Path and has served as Bio-Path’s President, Chief Executive Officer, Chief Financial Officer/Treasurer and Chairman of the Board since 2008. At the time of Bio-Path’s establishment in 2007, Mr. Nielsen licensed technology and targets from The University of Texas, MD Anderson Cancer Center and coordinated preclinical development, optimization and manufacturing of Bio-Path’s lead drug candidate, prexigebersen. Since that time, Mr. Nielsen has led the clinical advancement of prexigebersen into Phase 2 studies, the introduction of additional pipeline candidates and the Company’s public market debut. Prior to co-founding Bio-Path, Mr. Nielsen worked with several other companies, leading turnarounds and developing and executing on strategies for growth. Mr. Nielsen previously served as a director of Synthecon, Inc., a company developing 3D cell culture technology. Before entering the biotechnology sector, Mr. Nielsen was a lieutenant in the U.S. Naval Nuclear Power program where he was director of the physics department and was employed at Ford Motor Company in product development. Mr. Nielsen has a broad background in senior management and has significant negotiating experience. He holds engineering, mathematics and M.B.A. finance degrees from the University of California at Berkeley.

What is the salary of Peter Nielsen?

As the Chairman of the Board, President, Chief Executive Officer, Co-Founder, Chief Financial Officer и Treasurer of Bio-Path Inc, the total compensation of Peter Nielsen at Bio-Path Inc is $734,734. There are no executives at Bio-Path Inc getting paid more.

How old is Peter Nielsen?

Peter Nielsen is 71, he's been the Chairman of the Board, President, Chief Executive Officer, Co-Founder, Chief Financial Officer и Treasurer of Bio-Path Inc since 2008. There are 1 older and 5 younger executives at Bio-Path Inc. The oldest executive at Bio-Path Holdings Inc is Peter H. Nielsen MBA, 72, who is the Co-Founder, Chairman, CEO, Pres, CFO & Treasurer.

What's Peter Nielsen's mailing address?

Peter's mailing address filed with the SEC is 20651 Prince Creek Dr, Katy, TX 77450, USA.

Insiders trading at Bio-Path Inc

Over the last 16 years, insiders at Bio-Path Inc have traded over $171,456 worth of Bio-Path Inc stock and bought 1,226,067 units worth $451,466 . The most active insiders traders include Capital, Llc Armistice Capi..., Thomas E Garrison и Michael J. Garrison. On average, Bio-Path Inc executives and independent directors trade stock every 423 days with the average trade being worth of $156,477. The most recent stock trade was executed by Capital, Llc Armistice Capi... on 18 January 2019, trading 64,457 units of BPTH stock currently worth $171,456.

What does Bio-Path Inc do?

bio-path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary dnabilize™ technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. the company’s initial focus is in oncology. bio-path’s lead product candidate, prexigebersen, (bp1001), is in phase ii clinical trials for aml in combination with ldac in elderly de novo patients. the safety segment of the phase ii trial for prexigebersen + dasatinib in blast-phase and accelerated phase cml patients is expected to begin in 2017. bio-path’s second drug candidate, bp1002, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. the technology behind prexigebersen is called dnabilize™ technology. dnabilize is a liposomal antisense dna platform with two critical improvements in oligonucleotide therapeutics. the main benefits to the patient are, 1: we have never had a single patient experience thrombocytopen

Bio-Path Inc executives and stock owners

Bio-Path Inc executives and other stock owners filed with the SEC include:

• Peter Nielsen,
  Chairman of the Board, President, Chief Executive Officer, Co-Founder, Chief Financial Officer, Treasurer
• Peter H. Nielsen MBA,
  Co-Founder, Chairman, CEO, Pres, CFO & Treasurer
• Douglas Morris,
  Director, Secretary, Director of Investor Relations
• Douglas P. Morris,
  Co-Founder, Director of Investor Relations, Sec. & Director
• Martina Molsbergen,
  Independent Director
• Heath Cleaver,
  Independent Director
• Paul Aubert,
  Independent Director
• Victoria Lake Rac,
  Regulatory Consultant
• Dr. Jeffery Lancet M.D.,
  Consultant
• Dr. Thomas A. Walker Ph.D.,
  Consultant
• Dr. Alan MacKenzie Ph.D.,
  Consultant
• Dr. Ana Tari Ashizawa Ph.D., MBA,
  Sr. VP of Research, Devel. & Clinical Design
• Anthony Price,
  Sr. VP of Fin., Accounting & Admin.
• Amy Sing,
  Director
• Ulrich W. Mueller,
  Chief Operating Officer
• Michael J. Garrison,
  Director
• Mark P Colonnese,
  Director
• Capital, Llc Armistice Capi...,
  
• Gillian C Ivers Read,
  Director
• Thomas E Garrison,
  Director
• Aline Sherwood,
  Director